Maxx Chatsko

Maxx Chatsko

TMFBlacknGold

Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.

Recent articles

stock down angry fist

Amyris Reports Its Largest First-Half Operating Loss Since 2012

A growing balance of deferred cost of product revenue suggests business fundamentals might be significantly worse than reported.


arrow up shelves

Here's Why Shares of Editas Medicine and Beam Therapeutics Are Soaring Today

A rumored merger has investors excited, although details are scarce.


410 binoculars kid

What to Watch When Twist Bioscience Reports Fiscal Q3 Results

Can the company possibly live up to its lofty market valuation?


076 arrow dude getty

Renewable Energy Group Posts Surprise Q2 Profit

The biomass-based diesel manufacturer smashed through its own lowly expectations thanks to a boost from state and federal incentives.


327 pipeline

Does the Hydrogen Economy Have a Pipeline Problem?

Manufacturing hydrogen from renewable energy sounds great, but there are significant limitations to transporting hydrogen fuels.

022 roller coaster

NeoGenomics Slumps in Q2 but Readies for Second-Half Rebound

The oncology reference lab never stopped investing in near- and long-term opportunities. It expects that to pay off -- and soon.


410 binoculars kid

What to Watch When Albemarle Reports Q2 Earnings

The specialty chemicals manufacturer is expected to struggle in 2020, but it has undertaken significant efforts to preserve long-term business fundamentals.


464 diesel truck

What to Watch When Renewable Energy Group Reports

The renewable fuels manufacturer is contending with a historic slowdown in demand for transportation fuels. Are diesel fuels more insulated from uncertainty?


058 by the numbers

Repligen Reports Record Quarter, Increases 2020 Guidance

The coronavirus pandemic has done little to hamper the growth trajectory of the bioprocess engineering leader.


dude tossing stacks

Here's Why Fluidigm Soared as Much as 58.6% Today

The struggling laboratory hardware developer received a $37 million infusion to tackle the coronavirus pandemic.

202 yellow traffic light

Coronavirus Vaccine Stocks: Investors Cannot Overlook These Risks

If coronavirus vaccine development efforts are a race, then pharmaceutical companies will need to hurdle more than clinical trials to be successful.


076 arrow dude getty

Here's Why MediciNova Is Soaring Today

The small-cap pharmaceutical company announced a collaboration to develop a coronavirus vaccine.


arrow up shelves

Here's Why Amyris Stock Rose as Much as 12.2% Today

The synthetic biology pioneer announced a collaboration for its vaccine adjuvant ambitions.


242 hydrogen leaf

Missing in the Hydrogen Economy Pitch: The Tax Credit Cliff for Fuel Cells

Fuel-cell manufacturers have fixed the eyes of investors on the growth potential of a hydrogen economy, but it might be distracting from a looming financial crunch.


034 greedy businessman

Twist Bioscience Has Gained 186% in 2020. Is the Synbio Stock a Buy?

The company's $2.7 billion valuation is being driven by the coronavirus pandemic and federal stimulus. It doesn't appear sustainable.

248 nuclear cooling towers

U.S. Uranium Output Hit an All-Time Low in 2019. Does It Matter?

Nuclear power plants provide roughly 20% of the nation's electricity, but domestic uranium production could have met just 0.4% of fuel requirements last year.


dude pointing up

2 Stocks to Hold for the Next 20 Years

Two decades is a long time, but these up-and-coming biopharma companies could earn significantly larger valuations in that span.


000 businessman celebrate sad

Fuel Cell Investors Shouldn't Get Too Caught Up in the Hydrogen Economy Just Yet

Dreams of a hydrogen future have sent fuel cell stocks soaring in 2020, but investors might get burned by the technological hype.


people re cut outs

Renewable Energy Is the New Growth Driver for Dominion Energy

The unexpected sale of its gas transmission and storage business makes regulated utility operations, and renewable energy, more important than ever.


534 question cards wooden box

Is Neoleukin Therapeutics a Buy?

The drug developer has an intriguing technology platform and expects to enter clinical trials before the end of 2020, but there are a few things investors cannot overlook.